צמיחת מכירות ב-12 חודשים נגררים: exscientia.ai (EXAI)

Exscientia plc (EXAI) is currently focusing on the integration of algorithms and teams following a large-scale merger, temporarily halting new M&A deals. The trailing 12-month revenue change chart visualizes the effect of this restructuring, where this metric equals -4.10. Exscientia plc (EXAI) leads in generative molecule design via the Centaur system, while its digital approach to research minimizes biochemical waste, aligning with ESG principles.

Unstable revenue growth rates create risks for asset valuation, which is why year-over-year sales dynamics using the TTM methodology smooth out quarterly volatility by measuring the real revenue trend over a rolling year. For Exscientia plc (EXAI), this indicator reflects the commercial efficiency of integrating AI into drug discovery, allowing investors to distinguish one-off partnership successes from the sustainable scaling of the technological platform.